These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 12111105

  • 1. Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer.
    Booser DJ, Esteva FJ, Rivera E, Valero V, Esparza-Guerra L, Priebe W, Hortobagyi GN.
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):6-8. PubMed ID: 12111105
    [Abstract] [Full Text] [Related]

  • 2. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer.
    Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z, Booser DJ, Hortobagyi GN.
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):299-302. PubMed ID: 11914909
    [Abstract] [Full Text] [Related]

  • 3. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
    Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P, Batter V, Ngalula-Kabanga E, Dittrich C, Piccart M.
    Eur J Cancer; 2006 May; 42(7):882-7. PubMed ID: 16520033
    [Abstract] [Full Text] [Related]

  • 4. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG, Hemsen A, Karbe I, Lautenschläger C, Persing M, Thomssen C.
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of liposomal annamycin.
    Booser DJ, Perez-Soler R, Cossum P, Esparza-Guerra L, Wu QP, Zou Y, Priebe W, Hortobagyi GN.
    Cancer Chemother Pharmacol; 2000 Jun; 46(5):427-32. PubMed ID: 11127949
    [Abstract] [Full Text] [Related]

  • 6. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
    Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V, Breast Cancer Committee of the Hellenic Oncology Research Group.
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
    [Abstract] [Full Text] [Related]

  • 7. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up.
    Taiwanese Gynecologic Oncology GroupGynecologic Oncology Service, Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taipei, Taiwan., Chou HH, Wang KL, Chen CA, Wei LH, Lai CH, Hsieh CY, Yang YC, Twu NF, Chang TC, Yen MS.
    Gynecol Oncol; 2006 Jun; 101(3):423-8. PubMed ID: 16325239
    [Abstract] [Full Text] [Related]

  • 8. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
    Rose PG.
    Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG, Smrekar M, Haba P, Fusco N, Rodriguez M.
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [Abstract] [Full Text] [Related]

  • 10. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J, Camara O, Schmidt M, Mahner S, Seipelt G, Otremba B, Schmalfeldt B, Tesch H, Lorenz-Schlüter C, Oskay-Ozcelik G, North-Eastern German Society of Gynecological Oncology.
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [Abstract] [Full Text] [Related]

  • 11. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
    Oskay-Oezcelik G, Koensgen D, Hindenburg HJ, Klare P, Schmalfeldt B, Lichtenegger W, Chekerov R, Al-Batran SE, Neumann U, Sehouli J, Ovarian Cancer Study Group of the North-Eastern Germany Society of Gynecological Oncology (NOGGO).
    Anticancer Res; 2008 Aug; 28(2B):1329-34. PubMed ID: 18505074
    [Abstract] [Full Text] [Related]

  • 12. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Bourgeois H, Ferru A, Lortholary A, Delozier T, Boisdron-Celle M, Abadie-Lacourtoisie S, Joly F, Chieze S, Chabrun V, Gamelin E, Tourani JM.
    Am J Clin Oncol; 2006 Jun; 29(3):267-75. PubMed ID: 16755180
    [Abstract] [Full Text] [Related]

  • 13. Bisantrene, an active new drug in the treatment of metastatic breast cancer.
    Yap HY, Yap BS, Blumenschein GR, Barnes BC, Schell FC, Bodey GP.
    Cancer Res; 1983 Mar; 43(3):1402-4. PubMed ID: 6825109
    [Abstract] [Full Text] [Related]

  • 14. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
    Fujisaka Y, Horiike A, Shimizu T, Yamamoto N, Yamada Y, Tamura T.
    Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
    Rose PG, Blessing JA, Lele S, Abulafia O.
    Gynecol Oncol; 2006 Aug; 102(2):210-3. PubMed ID: 16478630
    [Abstract] [Full Text] [Related]

  • 16. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
    Hong RL, Lin CH, Chao TY, Kao WY, Wang CH, Hsieh RK, Hwang WS.
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
    [Abstract] [Full Text] [Related]

  • 17. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G, Blessing J, Hanjani P, Kramer P, Gynecologic Oncology Group.
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [Abstract] [Full Text] [Related]

  • 18. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study.
    Vorobiof DA, Rapoport BL, Chasen MR, Slabber C, McMichael G, Eek R, Mohammed C.
    Breast; 2004 Jun; 13(3):219-26. PubMed ID: 15177425
    [Abstract] [Full Text] [Related]

  • 19. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women > or = 65 years of age.
    Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E, Cennamo G, Rotundo MS, Tagliaferri P, Caraglia M, Del Prete S.
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):285-92. PubMed ID: 17922275
    [Abstract] [Full Text] [Related]

  • 20. Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution.
    Bernardi D, Errante D, Stefani M, Salvagno L.
    Breast; 2010 Dec; 19(6):549-50. PubMed ID: 20542696
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.